We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+9.04%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$185M
AUM Growth
+$7.74M
Cap. Flow
+$12.1M
Cap. Flow %
6.51%
Top 10 Hldgs %
70.79%
Holding
30
New
10
Increased
8
Reduced
8
Closed
3

Top Buys

1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.82M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$9.25M
3
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$8.89M
4
NEOS
Neos Therapeutics, Inc
NEOS
+$4.27M
5
CUTR
Cutera, Inc.
CUTR
+$3.82M

Top Sells

1
SCLN
Sciclone Pharmaceuticals Inc
SCLN
+$14.5M
2
ALR
Alere Inc
ALR
+$8.43M
3
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$7.98M
4
CORV
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
+$4.21M
5
ALIM
Alimera Sciences
ALIM
+$3.42M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIVE
1
DELISTED
VIVEVE MED INC
VIVE
$27.5M 14.86%
3,850
– –
ENTA icon
2
Enanta Pharmaceuticals
ENTA
$400M
$17.7M 9.56%
492,265
+307,166
+166% +$9.82M
NVLN
3
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$17.1M 9.23%
1,852,395
+291,908
+19% +$2.81M
SCTL
4
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$12.9M 6.95%
2,040,081
-1,164,782
-36% -$7.98M
VNDA icon
5
Vanda Pharmaceuticals
VNDA
$327M
$11.2M 6.03%
685,086
+641,786
+1,482% +$9.25M
VCEL icon
6
Vericel Corp
VCEL
$2.38B
$9.84M 5.31%
2,980,570
-284,753
-9% -$781K
BDSI
7
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$9.74M 5.26%
3,477,673
+632,853
+22% +$1.34M
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.15M 4.94%
3,576,189
+59,700
+2% +$163K
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
$8.25M 4.45%
747,863
-4,547
-0.6% -$45.7K
CPIX icon
10
Cumberland Pharmaceuticals
CPIX
$102M
$7.76M 4.19%
1,109,167
+369,250
+50% +$2.44M
CTIC
11
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$7.56M 4.08%
+2,284,381
New +$8.89M
CORV
12
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$7.21M 3.89%
1,595,549
-1,161,711
-42% -$4.21M
VCYT icon
13
Veracyte
VCYT
$4.72B
$7.2M 3.89%
864,695
+286,495
+50% +$2.34M
ALR
14
DELISTED
Alere Inc
ALR
$5.02M 2.71%
100,000
-175,000
-64% -$8.43M
DRRX
15
DELISTED
DURECT Corp
DRRX
$4.96M 2.68%
317,599
+37,461
+13% +$427K
CUTR
16
DELISTED
Cutera, Inc.
CUTR
$4.53M 2.45%
+175,000
New +$3.82M
NEOS
17
DELISTED
Neos Therapeutics, Inc
NEOS
$4.13M 2.23%
+565,100
New +$4.27M
CORI
18
DELISTED
Corium International, Inc.
CORI
$3.08M 1.67%
+413,568
New +$2.46M
BSTC
19
DELISTED
BioSpecifics Technologies Corp.
BSTC
$2.96M 1.6%
+59,878
New +$3.14M
SCLN
20
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$2.38M 1.28%
216,307
-1,446,974
-87% -$14.5M
TRIB
21
Trinity Biotech
TRIB
$6.79M
$1.87M 1.01%
62,399
-7,984
-11% -$226K
ASRT
22
DELISTED
Assertio
ASRT
$1.36M 0.73%
+2,110
New +$1.41M
CASM
23
DELISTED
CAS Medical Systems, Inc.
CASM
$1.04M 0.56%
+900,366
New +$1.03M
AMRN
24
Amarin Corp
AMRN
$292M
$302K 0.16%
+3,750
New +$233K
ALIM
25
DELISTED
Alimera Sciences
ALIM
$257K 0.14%
12,322
-159,430
-93% -$3.42M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Stonepine Capital Management held 30 positions worth $185M, up 4.4% from $177M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Stonepine Capital Management deployed $12.1M of net new capital in Q2 2017, opening 10 new positions and adding to 8 existing holdings. Its largest new stake was CTI BioPharma Corp. (DE) Common Stock: 2,284,381 shares worth $7.56M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Sciclone Pharmaceuticals Inc, an estimated $14.5M trimmed.

  • Stonepine Capital Management's largest Q2 2017 buy was CTI BioPharma Corp. (DE) Common Stock: 2,284,381 shares worth $7.56M.
  • Stonepine Capital Management added most to Enanta Pharmaceuticals in Q2 2017, an estimated $9.82M increase.
  • Stonepine Capital Management's biggest Q2 2017 reduction was Sciclone Pharmaceuticals Inc, cutting an estimated $14.5M.
  • Stonepine Capital Management fully exited Emergent Biosolutions in Q2 2017, selling an estimated $1.58M.
  • Stonepine Capital Management's ten largest holdings make up 71% of its $185M portfolio in Q2 2017.
  • Stonepine Capital Management opened 10 new positions and closed 3 in Q2 2017.
  • Stonepine Capital Management's portfolio value rose 4.4% quarter-over-quarter to $185M.

Based on Stonepine Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.